FibroTargets - Targeting cardiac fibrosis for heart failure treatment
Call/Topic: FP7-HEALTH-2013-INNOVATION-1: Discovery research to reveal novel targets for cardiovascular disease treatment
Project duration: 09/2013–09/2017
Total costs: € 6.000.000
Contribution MUW: € 680.000
The Medical University of Vienna acts as a project partner led by Prof. Dr. Mariann Gyöngyösi, Clinical Department of Internal Medicine II, Division of Cardiology.
Project coordinator is Prof. Dr. Faiez Zannad, Hôpital Brabois, FRANCE.
Consortium: 11 partners
Targeting cardiac fibrosis for heart failure treatment
FIBROTARGETS sets out to develop a European Union (EU) led, global research consortium that focuses on Myocardial Interstitial Fibrosis (MIF) in heart failure (HF), with the aim of validating new targets for further drug discovery and development to prevent/decrease MIF and slowdown the transition to and progression of HF.
The FIBROTARGETS project will lead to:
- the validation of biology-driven targets which, in turn,
- will result in both a better knowledge of the pathophysiology and modulation of myocardial interstitial fibrosis (MIF),
- identification and screening of small molecules with therapeutic potential aimed at the most promising biotargets,
- improved individualized options for HF prevention and treatment.
Ultimately, the FIBROTARGETS data will increase the probability of identifying new therapeutic molecular targets, druggable hits, and biomarkers with high clinical applicability
The Medical University of Vienna is responsible for the large animal experiments to treat myocardial infarction associated with cardiac fibrosis. Active components and concepts will be tested in large animals in comparable conditions to human treatment. These experiments will show the feasibility, safety and efficacy of the new therapeutic approaches for implementing them into the clinics.
Arbeitsgruppe Univ. Prof. Univ.-Doz. Dr. Mariann Pavone-Gyöngyösi